These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30957299)

  • 1. Rapid and extensive intrahepatic metastatic recurrence of hepatocellular carcinoma with very small portal vein tumor thrombus after surgery and sustained virological response of HCV with direct-acting antivirals.
    Kim SK; Kim SR; Imoto S; Shida N; Fujii Y; Fujii T; Kido M; Kinoshita H; Koma YI; Hayashi Y; Matsuoka T; Kudo M
    Pathol Int; 2019 May; 69(5):306-308. PubMed ID: 30957299
    [No Abstract]   [Full Text] [Related]  

  • 2. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    Ann Surg Oncol; 2019 Dec; 26(13):4566-4575. PubMed ID: 31602577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
    Tsujita E; Maeda T; Kayashima H; Harada N; Tsutsui S; Matsuda H; Kinjo N; Ikeda Y; Morita M; Ishida T
    Hepatogastroenterology; 2015; 62(137):157-63. PubMed ID: 25911888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
    Ooka Y; Miho K; Shuntaro O; Nakamura M; Ogasawara S; Suzuki E; Yasui S; Chiba T; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N; Mochizuki H; Omata M
    Hepatol Int; 2018 Nov; 12(6):523-530. PubMed ID: 30242733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of direct-acting antivirals for hepatitis C viral infection and association with intrahepatic cholangiocarcinoma: Is there a linkage?
    Vakiti A; Cho MH; Lee W; Liang JJ; Lalos AT; Fishbein DA
    J Oncol Pharm Pract; 2019 Oct; 25(7):1743-1748. PubMed ID: 30253731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C.
    Tsujita E; Yamashita Y; Takeishi K; Maeda T; Takaki S; Mori N; Aisaka Y; Furukawa Y; Shirabe K; Ishida T; Maehara Y
    Hepatogastroenterology; 2013; 60(128):2048-54. PubMed ID: 24088310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].
    Liu X; Gao YH; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):944-947. PubMed ID: 29325299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
    Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
    Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma.
    Gon H; Kido M; Tanaka M; Kinoshita H; Komatsu S; Tsugawa D; Awazu M; Toyama H; Matsumoto I; Itoh T; Fukumoto T
    Surgery; 2018 Nov; 164(5):1014-1022. PubMed ID: 30093272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Shinkawa H; Hasegawa K; Arita J; Akamatsu N; Kaneko J; Sakamoto Y; Kokudo N
    Ann Surg Oncol; 2017 Oct; 24(11):3196-3202. PubMed ID: 28707053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
    Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals.
    Guardigni V; Cento V; Ianniruberto S; Badia L; Aragri M; Conti M; Perno CF; Viale P; Ceccherini-Silberstein F; Verucchi G
    Infection; 2018 Oct; 46(5):717-720. PubMed ID: 29804205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
    World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapidly growing hepatocellular carcinoma recurrence during direct-acting antiviral treatment for chronic hepatitis C.
    Yamashita N; Tanimoto H; Shimoda S; Komori A; Nomura H
    Clin J Gastroenterol; 2018 Dec; 11(6):497-500. PubMed ID: 29948818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    Hassany M; Elsharkawy A; Maged A; Mehrez M; Asem N; Gomaa A; Mostafa Z; Abbas B; Soliman M; Esmat G
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):876-881. PubMed ID: 29727383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.